迈威生物：关于继续使用部分暂时闲置募集资金进行现金管理的公告

Core Viewpoint - Maiwei Biotech announced the decision to utilize up to 800 million yuan of temporarily idle raised funds for cash management over a 12-month period, with the option for rolling use [1] Group 1: Financial Management - The net amount of raised funds as of June 30, 2025, is approximately 3.303 billion yuan [1] - 48.45% of the raised funds have been invested in antibody industrialization and other projects [1] - The highest single-day investment in cash management over the last 12 months was about 357 million yuan, with a principal amount of 38.77 million yuan yet to be recovered [1]